Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900241 | 0.83 | ALDH1A1 (0.38) | MEN1KMT2AMAPTBTK | |
| SCHEMBL19873878 | 0.83 | HTR2C (0.42) | HTR2CHTR2AIDH1CHRM3CHRM2 | |
| SCHEMBL19874007 | 0.78 | HTR2C (0.40) | HTR2CHTR2ACHRM3CHRM2 | |
| SCHEMBL19873973 | 0.70 | HTR2A (0.39) | HTR2CHTR2ADRD2TLR8TLR7 | |
| SCHEMBL6166885 | 0.65 | CHRM3 (0.52) | HTR2CHTR2AMEN1KMT2ACHRM3 | |
| SCHEMBL4079721 | 0.65 | PDE3B (0.41) | HTR2CKMT2A | |
| SCHEMBL2262403 | 0.64 | CHRM3 (0.57) | HTR2CHTR2AKMT2ACHRM3CHRM2 | |
| SCHEMBL3963894 | 0.64 | PDE3B (0.40) | HTR2CHTR2AKMT2ACHRM3CHRM2 | |
| SCHEMBL4079724 | 0.64 | PDE3B (0.40) | HTR2CHTR2AKMT2A | |
| SCHEMBL30178610 | 0.64 | ALDH1A1 (0.51) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | HTR2C 291/4885HTR2A 231/4885IDH1 3084/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | HTR2C 245/4885HTR2A 183/4885IDH1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.